Information  X 
Enter a valid email address

Microsaic Systems (MSYS)

  Print      Mail a friend

Tuesday 19 February, 2019

Microsaic Systems

Notice of Results

RNS Number : 3834Q
Microsaic Systems plc
19 February 2019
 

19 February 2019

 

Microsaic Systems plc

 

("Microsaic", "Microsaic Systems" or the "Company")

 

Notice of Results

 

Microsaic Systems plc (AIM: MSYS), the developer of point of need mass spectrometry instruments, announces that the Company will be reporting final results for the 12 months ended 31 December 2018 on Monday 11 March 2019.

 

 

Enquiries:

 

 

Microsaic Systems plc

Glenn Tracey, CEO

Bevan Metcalf, FD

+44 (0) 1483 751 577

 

N+1 Singer (Nominated Adviser & Broker)

Shaun Dobson / George Tzimas (Corporate Finance)

Tom Salvesen (Corporate Broking)

 

 

+44 (0) 20 7496 3000

IFC Advisory Ltd (Financial PR)

Graham Herring

Heather Armstrong

Florence Chandler

+44 (0) 20 3934 6630

 

 

About Microsaic Systems

Microsaic Systems plc (AIM: MSYS) is a high technology company developing chip-based, bench-top and point-of-analysis mass spectrometry ("MS") instruments that are designed to improve the efficiency of pharmaceutical R&D and manufacturing.  The Company works with established global life science companies to co-develop new solutions to improve productivity in the development of small molecule and novel biologic (peptides, antibodies) medicines.  MS is a powerful method of analysis to enable earlier decision making relating to product identification, purity and bioactivity, and is the analytical technique of choice for biochemists across many industry sectors.

 

The Microsaic's compact MiD® MS systems retain the functionality of larger conventional MS systems, while being easier to use by non-specialists, and consume less energy and have lower running costs. For more information, please go to www.microsaic.com.  


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NORLLFVFFVITLIA

a d v e r t i s e m e n t